Isabelle Moulon

What Does Brexit Mean for Health Care and Medical Research?

Aisling Burnand, Pierre Meulien, Isabelle Moulon, Margaret Anderson, Annalisa Jenkins

This panel outlines a paradigm shift in biomedical research where academia, industry, regulators, and patients collaborate through massive initiatives like the €5 billion Innovative Medicines Initiative to overcome historical silos and complex disease challenges. Key figures including Annalisa Jenkins of Dimension Therapeutics and Isabel Mugon of the European Medicines Agency highlighted how the externalization of innovation and early patient integration are accelerating drug development, even as Brexit risks to financial and human capital require new government support. The collective consensus emphasizes that while healthcare systems lag behind rapid scientific advances, the sector is moving toward a unified, data-driven ecosystem prioritizing real-world evidence and measurable patient outcomes over isolated achievements.